Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,655

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cremophor EL

Gelderblom, H, Verweij, J, Nooter, K, Sparreboom, A·2001·European Journal of Cancer
DOI 10.1016/s0959-8049(01)00171-x
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0959-8049(01)00171-x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 74

  1. Jonkman-de Vries, 1994, Pharmaceutical development of (investigational) anticancer agents for parenteral use — a review, ECC Newsletter, 3, 11
  2. Pinedo, 1986, Review, Med. Oncol. Tumor Pharmacother., 3, 63, 10.1007/BF02934555 · doi:10.1007/bf02934555
  3. Liu, 1997, Patient preferences for oral versus intravenous palliative chemotherapy, J. Clin. Oncol., 15, 110, 10.1200/JCO.1997.15.1.110 · DOI · Paper page
  4. Hoffman, 1984, Polyoxythylenglycerol triricinoleat 35 DAC 1979, Pharm. Zeit., 129, 1730
  5. Wani, 1971, Plant antitumor agents. VI, J. Am. Chem. Soc., 93, 2325, 10.1021/ja00738a045 · DOI · Paper page
  6. Adams, 1993, Taxol, J. Natl. Cancer Inst. Monogr., 15, 141
  7. Rowinsky, 1993, Clinical toxicities encountered with paclitaxel (Taxol), Semin. Oncol., 20, 1
  8. Weiss, 1990, Hypersensitivity reactions from Taxol, J. Clin. Oncol., 8, 1263, 10.1200/JCO.1990.8.7.1263 · DOI · Paper page
  9. Eisenhauer, 1994, European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer, J. Clin. Oncol., 12, 2654, 10.1200/JCO.1994.12.12.2654 · DOI · Paper page
  10. Szebeni, 1998, Complement activation by Cremophor EL as a possible contributer to hypersensitivity to paclitaxel, J. Natl. Cancer Inst., 90, 300, 10.1093/jnci/90.4.300 · DOI · Paper page
  11. Watkins, 1997, Adverse reactions to intravenous anaesthetic induction agents, Br. Med. J., 2, 1084, 10.1136/bmj.2.6094.1084-a · doi:10.1136/bmj.2.6094.1084-a
  12. Hüttel, 1980, Complement-mediated reactions to diazepam with Cremophor as solvent (stesolid MR), Br. J. Anaesth., 52, 77, 10.1093/bja/52.1.77 · doi:10.1093/bja/52.1.77
  13. van Zuylen, 2000, Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients, Anticancer Drugs, 11, 331, 10.1097/00001813-200006000-00003 · DOI
  14. Lorenz, 1977, Histamine release in dogs by Cremophor EL and its derivatives, Agent Actions, 7, 63, 10.1007/BF01964882 · DOI · Paper page
  15. Rowinsky, 1991, Cardiac disturbances during the administration of Taxol, J. Clin. Oncol., 9, 1704, 10.1200/JCO.1991.9.9.1704 · DOI · Paper page
  16. Theis, 1995, Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance, J. Clin. Oncol., 13, 2508, 10.1200/JCO.1995.13.10.2508 · doi:10.1200/jco.1995.13.10.2508
  17. Volcheck, 1998, Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine, Am. Allergy Asthma Immunol., 80, 159, 10.1016/S1081-1206(10)62949-3 · DOI
  18. Bagnarello, 1977, Unusual lipoproteins induced by the vehicle of miconazole, N. Eng. J. Med., 296, 497, 10.1056/NEJM197703032960907 · doi:10.1056/nejm197703032960907
  19. Kongshaug, 1991, Interaction of Cremophor EL with human serum, Int. J. Biochem., 23, 473, 10.1016/0020-711X(91)90176-N · DOI
  20. Woodburn, 1994, The alteration of plasma lipoproteins by Cremophor EL, Photochem. Photobiol. B, 22, 197, 10.1016/1011-1344(93)06968-9 · doi:10.1016/1011-1344(93)06968-9
  21. Sykes, 1994, Effects of Cremophor EL on distribution of taxol to serum lipoproteins, Br. J. Cancer, 70, 401, 10.1038/bjc.1994.317 · DOI
  22. Kessel, 1995, Fractionation of Cremophor EL delineates components responsible for plasma alterations and multidrug resistance reversal, Oncol. Res., 7, 207
  23. Shimomura, 1998, Effects of Taxol on blood cells, Lancet, 352, 541, 10.1016/S0140-6736(05)79249-7 · doi:10.1016/s0140-6736(05)79249-7
  24. Windebank, 1994, Potential neurotoxicity of the solvent vehicle for cyclosporine, J. Pharmacol. Exp. Ther., 268, 1051
  25. Lesser, 1995, The distribution of systemically administered [3H]paclitaxel in rats, Cancer Chemother. Pharmacol., 37, 173
  26. de Groen, 1987, Central nervous system toxicity after liver transplantation, N. Eng. J. Med., 317, 861, 10.1056/NEJM198710013171404 · DOI · Paper page
  27. Sparreboom, 1997, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proc. Natl. Acad. Sci. USA, 94, 2031, 10.1073/pnas.94.5.2031 · DOI · Paper page
  28. Verweij, 1994, Paclitaxel (Taxol) and docetaxel (Taxotere), Ann. Oncol., 5, 495, 10.1093/oxfordjournals.annonc.a058903 · DOI · Paper page
  29. Podratz, 1993, Dialyzer associated neurotoxicity due to a change in fatty acid structure, Trans. Am. Soc. Neurochem., 24, 229
  30. Brat, 1992, Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma, J. Pharmacol. Exp. Ther., 261, 803
  31. Woodcock, 1990, Reversal of multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs, Cancer Res., 50, 4199
  32. Friche, 1990, The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor, Cancer Commun., 2, 297
  33. Schuurhuis, 1990, The polyethylene castor oil Cremophor EL modifies multidrug resistance, Br. J. Cancer, 62, 591, 10.1038/bjc.1990.335 · DOI
  34. Chervinsky, 1993, Cremophor EL enhances Taxol efficacy in a multi-drug resistant C13000 neuroblastoma cell line, Anticancer Res., 13, 93
  35. Riehm, 1972, Potentiation of drug effect by Tween 80 in hamster cells resistant to actinomycin D and daunomycin, Cancer Res., 32, 1195
  36. Coon, 1991, Solutol HS 15, nontoxic polyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance, Cancer Res., 50, 4199
  37. Zordan-Nudo, 1993, Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance, Cancer Res., 53, 897
  38. Woodcock, 1992, Reversal of multidrug resistance by surfactants, Br. J. Cancer, 66, 62, 10.1038/bjc.1992.217 · DOI · Paper page
  39. Slater, 1995, Comparison of cyclosporin A, verapamil, PSC-833 and Cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias, Leuk. Res., 19, 543, 10.1016/0145-2126(95)00029-N · doi:10.1016/0145-2126(95)00029-n
  40. Watanabe, 1996, Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models, Anticancer Drugs, 7, 825, 10.1097/00001813-199611000-00002 · doi:10.1097/00001813-199611000-00002
  41. Sparreboom, 1998, Disposition of Cremophor EL limits the potential of the multidrug resistance phenotype in vivo, Clin. Cancer Res., 4, 1937
  42. Nooter, 1994, Clinical relevance of P-glycoprotein expression in hematological malignancies, Leuk. Res., 18, 233, 10.1016/0145-2126(94)90025-6 · DOI
  43. Fjällskog, 1993, Is Cremophor EL, the solvent for paclitaxel, cytotoxic?, Lancet, 342, 873, 10.1016/0140-6736(93)92735-C · DOI
  44. Nygren, 1995, The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL, Br. J. Cancer, 71, 478, 10.1038/bjc.1995.97 · doi:10.1038/bjc.1995.97
  45. Csóka, 1997, Differential activity of Cremophor EL and Paclitaxel in patients' tumour cells and human carcinoma cell lines in vitro, Cancer, 79, 1225, 10.1002/(SICI)1097-0142(19970315)79:6<1225::AID-CNCR23>3.0.CO;2-0 · doi:10.1002/(sici)1097-0142(19970315)79:6<1225::aid-cncr23>3.0.co;2-0
  46. Bégin, 1988, Polyunsaturated fatty acid-induced cytotoxicity against tumour cells and its relationship to lipid peroxidation, J. Natl. Cancer Inst., 80, 188, 10.1093/jnci/80.3.188 · DOI
  47. Siegel, 1987, Cytotoxic effects of free fatty acids on ascites tumour cells, J. Natl. Cancer Inst., 78, 271
  48. Burton, 1991, Oncolytic effects of fatty acids in mice and rats, Am. J. Clin. Nutr., 53, 1082, 10.1093/ajcn/53.4.1082S · doi:10.1093/ajcn/53.4.1082s
  49. Liebmann, 1994, The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines, Cancer Chemother. Pharmacol., 33, 331, 10.1007/BF00685909 · DOI
  50. Webster, 1993, Measurement of CrEL following Taxol, J. Natl. Cancer Inst., 85, 1685, 10.1093/jnci/85.20.1685 · DOI
  51. Sparreboom, 1996, Determination of polyethylene-glyceroltriricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reverse-phase high-performance liquid chromatography, J. Chromatogr. B, 681, 355, 10.1016/0378-4347(95)00544-7 · doi:10.1016/0378-4347(95)00544-7
  52. Sparreboom, 1998, Quantification of Cremophor EL in human plasma samples using a calorimetric dye-binding microassay, Anal. Biochem., 255, 171, 10.1006/abio.1997.2467 · DOI
  53. Brouwer, 1998, Linearized colorimetric assay for Cremophor EL, Anal. Biochem., 261, 198, 10.1006/abio.1998.2746 · DOI
  54. Kunkel, 1999, Titrimetric determination of Cremophor EL in aqueous solutions and biofluids, J. Pharm. Biomed. Anal., 21, 911, 10.1016/S0731-7085(99)00212-5 · doi:10.1016/s0731-7085(99)00212-5
  55. Rischin, 1996, Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel, J. Natl. Cancer Inst., 88, 1297, 10.1093/jnci/88.18.1297 · doi:10.1093/jnci/88.18.1297
  56. Sparreboom, 1996, Nonlinear murine pharmacokinetics of paclitaxel results from the pharmaceutical vehicle Cremophor EL, Cancer Res., 56, 2112
  57. van Tellingen, 1999, Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice, Clin. Cancer Res., 5, 2918
  58. Meerum-Terwogt, 2000, Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients, Anticancer Drugs, 11, 687, 10.1097/00001813-200010000-00003 · doi:10.1097/00001813-200010000-00003
  59. Gelderblom, 1999, Disposition of [G-3H]paclitaxel in a patient with severely impaired renal function, Drug Metab. Dispos., 27, 1300
  60. Gianni, 1997, Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer, J. Clin. Oncol., 15, 1906, 10.1200/JCO.1997.15.5.1906 · DOI
  61. Ellis, 1999, Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL, Cancer Chemother. Pharmacol., 43, 13, 10.1007/s002800050857 · DOI
  62. Sparreboom, 1999, Cremophor EL-mediated alteration of paclitaxel distribution in human blood, Cancer Res., 59, 1454
  63. van Zuylen, 2001, Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles, Cancer Chemother. Pharmacol., 47, 309, 10.1007/s002800000215 · DOI
  64. Barre, 1988, Problems in therapeutic drug monitoring, Ther. Drug. Monit., 10, 133, 10.1097/00007691-198802000-00002 · doi:10.1097/00007691-198802000-00002
  65. van der Burg MEL, de Wit R, Stoter G, Verweij J. Phase I study of weekly cisplatin and weekly or 4-weekly taxol: a highly active regimen in advanced epithelial cancer. Proc Am Soc Clin Oncol 1998, 17, 1370 (abstr).
  66. Rowinsky, 1991, Sequences of taxol and cisplatin, J. Clin. Oncol., 9, 1692, 10.1200/JCO.1991.9.9.1692 · DOI · Paper page
  67. Huizing, 1993, Pharmacokinetics of paclitaxel in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer, J. Clin. Oncol., 15, 317, 10.1200/JCO.1997.15.1.317 · doi:10.1200/jco.1997.15.1.317
  68. de Vos, 1997, Differential modulation of cisplatin accumulation in leucocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL, Ann. Oncol., 8, 1145, 10.1023/A:1008215720081 · doi:10.1023/a:1008215720081
  69. Ma, 1996, Docetaxel and paclitaxel inhibit DNA adduct formation and intracellular accumulation of cisplatin in human leukocytes, Cancer Chemother. Pharmacol., 36, 382, 10.1007/s002800050401 · doi:10.1007/s002800050401
  70. Badary, 2000, Differential alteration of cisplatin myelotoxicity by the paclitaxel vehicle Cremophor EL, Naunyn-Schmiedeberg Arch. Pharmacol., 261, 339, 10.1007/s002109900193 · DOI
  71. Bertoncello, 1995, Haematopoietic radioprotection by Cremophor EL, Int. J. Radiat. Biol., 67, 57, 10.1080/09553009514550071 · doi:10.1080/09553009514550071
  72. Millward, 1998, Phase I trial of Cremophor EL with bolus doxorubicin, Clin. Cancer Res., 4, 2321
  73. Holmes, 1996, Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer, J. Clin. Oncol., 14, 2713, 10.1200/JCO.1996.14.10.2713 · DOI · Paper page
  74. van Zuylen, 2001, Role of formulation vehicles in taxane pharmacology, Invest. N. Drugs, 19, 125, 10.1023/A:1010618632738 · DOI · Paper page

Cited by

See all 1,655

Metadata

Authors
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2001-09
Volume
37
Issue
13
Pages
1590-1598
ISSN
0959-8049 (ISSN-L)
DOI
10.1016/s0959-8049(01)00171-x
OpenAlex
W2184694295
Cited by
1,655
References
1
FWCI
6.65
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cremophor EL. https://app.cochat.ai/papers/10.1016/s0959-8049(01)00171-x
The paper
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001). Cremophor EL. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(01)00171-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.